Ironwood Terminated Rights of Zurampic lesinurad and Duzallo lesinurad/allopurinol Deal with AZ
Shots:
- As per Ironwood Zurampic generated $1.1Mn in 2Q18 and $3.1 Mn in 2017- company to reduce 125 field sales employees
- This termination agreement is expected to save $75-$100Mn in FY19 expenses
- This deal was executed in 2016 with Ironwood paying $100Mn upfront followed by $15Mn milestone payment post approval in US along with single-digit royalties
/ article | Ref: Biocentury | Image: Forbes
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
